Lifespan of COVID‐19 living guideline recommendations: A survival analysis

Abstract Background NICE has maintained a portfolio of coronavirus disease 2019 (COVID‐19) living guidelines since March 2020. Recommendations within these living guidelines are subject to continuous surveillance and updates in response to triggers. However, the lifespan of individual living guideline recommendations and features that may impact whether a recommendation becomes out of date sooner is unknown. Objectives This study describes the length of time NICE COVID‐19 living guideline recommendations have remained valid. Methods All guidelines within NICE's COVID‐19 portfolio were included to determine the lifespan of living guideline recommendations. Data were collected on all recommendations that had been developed, undergone surveillance or updated between 1 March 2020 and 31 August 2022. The initial publication date, decision to update and updated publication date were extracted. Updates were labelled as major changes in evidence synthesis or minor changes without a substantial change in the evidence base. Any recommendation that had not been updated or withdrawn was censored. Survival analysis (Kaplan–Meier curve) was carried out to determine the lifespan of recommendations. Results Overall, 26 COVID‐19 living guidelines and 1182 recommendations were included in the analysis. Living recommendations had a median survival time of 739 days (interquartile range [IQR]: 332, 781). Based on recommendation type, intervention recommendations had a shorter survival time (354 days, IQR: 312, 775) compared to diagnosis (368 days, IQR: 328, 795), patient experience (733 days, IQR: 345, 795) and service delivery (739 days, IQR: 643, 781). Within intervention type, pharmacological recommendations had the shortest survival time versus nonpharmacological recommendations (335 days, IQR: 161, 775 vs. 775 days, IQR: 354, 775). Updates were published an average of 29.12 days following a surveillance decision. Conclusion Within living guidelines, some recommendations need to be updated sooner than others. This study outlines the value of a flexible responsive approach to surveillance according to the pace of change and expectation of update triggers.

Authors

Institutions

Publication Details

Journal
Clinical and Public Health Guidelines
Published
2024-08-31
DOI
https://doi.org/10.1002/gin2.12012
Primary Topic
Clinical practice guidelines implementation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lifespan of COVID‐19 living guideline recommendations: A survival analysis

Kate Kelley, Steve Sharp, Fiona Glen, Emma McFarlane et al.
Clinical and Public Health Guidelines
Clinical practice guidelines implementation
article

Lifespan of COVID‐19 living guideline recommendations: A survival analysis

Kate Kelley, Steve Sharp, Fiona Glen, Emma McFarlane, Maria Majeed, Toby Mercer, Debra Hunter
article en

Abstract

Abstract Background NICE has maintained a portfolio of coronavirus disease 2019 (COVID‐19) living guidelines since March 2020. Recommendations within these living guidelines are subject to continuous surveillance and updates in response to triggers. However, the lifespan of individual living guideline recommendations and features that may impact whether a recommendation becomes out of date sooner is unknown. Objectives This study describes the length of time NICE COVID‐19 living guideline recommendations have remained valid. Methods All guidelines within NICE's COVID‐19 portfolio were included to determine the lifespan of living guideline recommendations. Data were collected on all recommendations that had been developed, undergone surveillance or updated between 1 March 2020 and 31 August 2022. The initial publication date, decision to update and updated publication date were extracted. Updates were labelled as major changes in evidence synthesis or minor changes without a substantial change in the evidence base. Any recommendation that had not been updated or withdrawn was censored. Survival analysis (Kaplan–Meier curve) was carried out to determine the lifespan of recommendations. Results Overall, 26 COVID‐19 living guidelines and 1182 recommendations were included in the analysis. Living recommendations had a median survival time of 739 days (interquartile range [IQR]: 332, 781). Based on recommendation type, intervention recommendations had a shorter survival time (354 days, IQR: 312, 775) compared to diagnosis (368 days, IQR: 328, 795), patient experience (733 days, IQR: 345, 795) and service delivery (739 days, IQR: 643, 781). Within intervention type, pharmacological recommendations had the shortest survival time versus nonpharmacological recommendations (335 days, IQR: 161, 775 vs. 775 days, IQR: 354, 775). Updates were published an average of 29.12 days following a surveillance decision. Conclusion Within living guidelines, some recommendations need to be updated sooner than others. This study outlines the value of a flexible responsive approach to surveillance according to the pace of change and expectation of update triggers.

Clinical and Public Health GuidelinesVol. 1(4)
National Institute for Health and Care Excellence (GB)
Openalex Percentile: Top 78%
Clinical practice guidelines implementation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.